The method of treatment of chronic viral hepatitis

 

(57) Abstract:

The invention relates to medicine, Hepatology, gastroenterology and clinical lymphology, to methods of treatment of chronic viral hepatitis. Enter interferon traditional course during the first two weeks after catheter in the round ligament of the liver, which is injected and install using the laparoscopic technique, the treatment was repeated 3 times with an interval of 3 months. This treatment increases the efficacy of antiviral therapy with the use of moderate doses of interferon.

The invention relates to medicine, in particular of gastroenterology, Hepatology and clinical lymphology.

Currently, for the treatment of chronic viral hepatitis uses a variety of treatment regimens involving the use of different doses of interferon (from 1 to 10 million IU), multiplicity (1-3 times per week) and duration of treatment (from 3 months to 2 years). The main disadvantage of the existing treatment methods is their low efficiency (less than 50%). Closest to the present invention is a method of treatment of chronic viral hepatitis, providing for the introduction of drugs inheren manifests itself in its interaction with cells and consists in suppressing viral replication, stimulation of production of endogenous interferon and immunomodulating effect (Sorenson S. N., 1998).

We propose a method consisting in the introduction of interferon at a dose of 3 million IU every other day in the round ligament of the liver.

The technical result in the application of the proposed method is to increase the effectiveness of antiviral therapy using moderate doses of interferon using indirect lymphotropic therapy.

The method is as follows. The catheter is inserted into the round ligament of the liver and fixed it using the laparoscopic technique under surveillance. Interferon (IFN or Roferon or intron a) is dissolved in an appropriate solvent and introduced into the catheter at a dose of 3 million IU every other day infusion pump with a speed of 2-5 ml per hour. Infusion of interferon precedes the introduction of 5 ml of 0.25% solution of novocaine with a rate of 2-5 ml per hour. In the days when interferon is not used, the catheter is flushed with 5-10 ml of 0.25% solution of novocaine, which also introduces the infusion pump with the same speed. The treatment in this mode lasts 14 days, then the catheter is removed, and the patient goes to the traditional treatment to 3 million UNITS in the drug interferon is repeated after 3 and 6 months. The total duration of treatment with interferon is 1 year.

Under our supervision there were 12 patients with chronic active viral hepatitis (6 with hepatitis C, 3 hepatitis b, 3 hepatitis b+C). The diagnosis of chronic viral hepatitis was verified laboratory, histopathological, serological data, and PCR analysis. Patients was conducted indirect lymphotropic therapy is one of the drugs interferon at a dose of 3 million IU every other day introduction to the round ligament of the liver within 2 weeks. Compared with the original parameters after 2 weeks of treatment in patients with decreased activity of transaminases in plasma in 1,3-1,5 times. Further treatment within 3 months, the patients received intramuscular injections of the drug interferon at a dose of 3 million IU 3 times a week. After 3 and 6 months after initiation of therapy, patients underwent a second course of injection of interferon round ligament of the liver according to the same scheme. After 6 months of starting treatment for biochemical analysis of blood revealed persistent normalization of transaminase activity and signs of seroconversion, and after 1 year - resistant seroconversion, normal transaminase activity, the disappearance intralobular infiltrates tion of 12 (patient with chronic hepatitis B+C) signs of exacerbation.

Clinical example.

Patient T., 44, was admitted to the hospital with a diagnosis of chronic hepatitis C, activity II. The patient was assigned to therapy with Roferon a dose of 3 million IU every other day with the introduction of the drug in the round ligament of the liver. Conducted 3 course indirect lymphotropic therapy with interferon in the round ligament of the liver. Total treatment duration was 1 year. A survey conducted after 1 year of treatment, revealed no evidence of active inflammation in the liver, serological markers replication of hepatitis C virus were also negative. At follow-up at six months and a year after treatment with interferon is not marked exacerbation, transaminase activity steadfastly normal signs of replication of the hepatitis C virus is not detected, the morphological examination of necrosis and inflammatory infiltrates in the liver parenchyma is not detected.

Literature.

Sorenson S. N. Viral hepatitis SPb.: theSIS, 1998. - 325 C.

The method of treatment of chronic viral hepatitis, including the introduction of interferon in the traditional course, and wherein the interferon is administered during the first two weeks after Katya repeat 3 times with an interval of 3 months.

 

Same patents:

The invention relates to medicine, infectious diseases, and to methods of treatment of patients With viral hepatitis C with hemosiderosis of the liver

The invention relates to medicine, Hepatology, to methods of treatment of chronic viral hepatitis

The invention relates to medicine, in particular for the treatment of patients with liver diseases, and the development of a treatment method that increases the effectiveness of therapy by improving the hemodynamics of the liver

The invention relates to the field of medicine
The invention relates to medicine, in particular to Hepatology

The invention relates to new biologically active chemical compound, specifically to 3,28-di-O-nicotinate betulin (1), formula

< / BR>
showing hepatoprotective and anti-HIV activity

The invention relates to medicine, specifically to the creation of a plant for the treatment of viral hepatitis B and C and the method of its treatment

The invention relates to medicine, in particular ointments, medicinal purposes, mainly for the treatment of psoriasis

The invention relates to medicine, namely to substances that cause the induction of microsomal liver enzymes

The invention relates to medicine, namely to the drainage of intra - and extrahepatic bile ducts

The invention relates to medicine, namely to the drainage of intra - and extrahepatic bile ducts

The invention relates to medicine, namely to the drainage of intra - and extrahepatic bile ducts

The invention relates to medicine, namely to the drainage of intra - and extrahepatic bile ducts

The invention relates to medicine, namely to surgery, and is designed to provide connection to the small intestine to move liquids, preferably for conveying fluids, such as supply of nutrients specified in the intestine, as well as for diagnostics (introduction of a contrast agent for an x-ray studies of the intestine or for sampling the contents of the intestine or mucous membranes)

The invention relates to medicine, namely to surgery, and is designed to provide connection to the small intestine to move liquids, preferably for conveying fluids, such as supply of nutrients specified in the intestine, as well as for diagnostics (introduction of a contrast agent for an x-ray studies of the intestine or for sampling the contents of the intestine or mucous membranes)

The invention relates to medicine, namely to surgery, and is designed to provide connection to the small intestine to move liquids, preferably for conveying fluids, such as supply of nutrients specified in the intestine, as well as for diagnostics (introduction of a contrast agent for an x-ray studies of the intestine or for sampling the contents of the intestine or mucous membranes)

The invention relates to medicine, namely to surgery, and is designed to provide connection to the small intestine to move liquids, preferably for conveying fluids, such as supply of nutrients specified in the intestine, as well as for diagnostics (introduction of a contrast agent for an x-ray studies of the intestine or for sampling the contents of the intestine or mucous membranes)

The invention relates to medicine, namely to cardiovascular surgery

The invention relates to medical equipment and can be used in the manufacture of intravenous catheter

The invention relates to the field of medicine and relates to pharmaceutical compositions containing the c-kit-ligand and hematopoietic factor, a method of increasing levels of stem cells in the peripheral blood, an antagonist of c-kit ligand, antisense molecules of nucleic acid, the method of increasing levels of peripheral blood cells ex vivo
Up!